Medical network - on September 7, after the end of June sig pharmaceutical for traditional Chinese medicine formula particles in guangdong after pilot, xiangxue pharmacy released announcement, said received the guangdong food and drug supervision bureau approval, agreed to the company in accordance with the standard to carry out the traditional Chinese medicine formula particles in the pilot study. In addition to these two guangdong enterprises, in recent years, many enterprises have launched the strategic layout of traditional Chinese medicine tablets and Chinese medicine formula granules, and the results are becoming more and more obvious. In the first half of 2017, the sales growth of the four leading Chinese medicine companies in China was more than 10%, according to the listed company.
Table 1: performance of five listed pharmaceutical companies in the first half of 2017 (unit: billion yuan)
At present, A stock market sig pharmaceutical, xiangxue pharmacy, too on the dragon pharmaceutical business in Chinese medicine yinpian, red sun pharmaceutical and H shares of China's traditional Chinese medicine in traditional Chinese medicine formula particles is also fruitful business. What transcripts of the first half of 2017?
Kangmei pharmaceutical: the business growth of Chinese medicine has grown 35.81 percent
Figure 1. The operating income of various business sectors of kangmei pharmaceutical industry in the first half of the year (unit: billion yuan)
In the first half of 2017, kangmei's total operating income was 13.262 billion yuan, with a growth rate of 18.38 percent. In the first half of this year, China's traditional Chinese medicine and beverage business revenue exceeded 26.97 billion yuan, with a growth rate of 35.81 percent.
Chinese medicine yinpian sig pharmaceutical business in the industry in a leading position, the company has multiple support traditional Chinese medicine industry and technical innovation of public service platform, has built national enterprise technology center and post-doctoral research station, has a number of invention patents, exterior design and the software copyright. Company to undertake several national science and technology support program, first put forward and implementation of Chinese medicine yinpian small package and color scale management and participated in many national and provincial yinpian processing and quality standard, the traditional Chinese medicine classification standards, is the only national technology innovation demonstration enterprises and Chinese medicine yinpian intelligent manufacturing pilot demonstration enterprises.
Sig pharmaceutical co., said the deepening of the reform of medical and pharmaceutical bidding procurement, GMP certification and the flight check, let go of the traditional Chinese medicine formula particles pilot production such as limit, health care, environmental protection policy profoundly affects the future development of domestic pharmaceutical enterprises, is likely to cause certain influence to the company. Pharmaceutical announced on June 30, sig, according to the agreed by the food drug administration of guangdong province, the company has to carry out the traditional Chinese medicine formula particles in the province of pilot approval, predictably, sig pharmaceutical industry is in traditional Chinese medicine formula particles to make business.
Chinese traditional Chinese medicine: Chinese medicine formula granule, Chinese medicine yinpian revenue rise
Figure 2. Business income of Chinese traditional Chinese medicine in the first half of the year (RMB 100 million)
In the first half of 2017, China's traditional Chinese medicine (TCM) revenue reached 38.9 billion yuan, with a growth rate of 21.9%. In the first half of this year, the sales revenue of Chinese medicine formula granule business exceeded 25.4.3 billion yuan, with the growth rate of 23.8%, while the sales revenue of the first half of the traditional Chinese medicine business was more than 185 million yuan, and the growth rate was 493.2 percent.
Chinese herbal medicine, in the first half of 2017 the jiangyin day jiang pharmaceutical industry has achieved satisfactory results, realize the rapid growth of the business turnover, thanks to the support of national policy, such as increased health coverage area and public hospital keep on Chinese medicine yinpian (including formula particles) sales bonus, etc. Secondly, on the basis of the sales network covering 30 provinces, it will strengthen market penetration and hospital coverage, and realize the rapid expansion of terminal channels. Third, increase the academic promotion, and the average sales volume of the second and third grade hospitals increased significantly. Fourthly, the market of smart dispensing machine increased significantly, which further strengthened the market position.
In the first half of this year, the sales revenue of Chinese traditional Chinese medicine formulated by Chinese traditional medicines through dispensing machines increased significantly, to 753 million yuan, accounting for 29.6 percent of total sales. Currently, tianjiang and guangdong have installed 3,072 smart dispensing machines at 1,740 hospitals, with an average of 1.8 units per hospital. Smart dispensing machines can bring significant added value to hospitals, which can improve the prescription efficiency and improve the user experience. At present, the potential for development of national hospitals is still huge. Tianjiang pharmaceutical will actively promote the rapid growth of turnover through the installation of smart dispensing machines for more secondary hospitals.
China's traditional Chinese medicine (TCM) in order to speed up Chinese medicine yinpian industry layout, completed in November and December 2016 respectively m&a guizhou tongjitang Chinese medicine yinpian tongjitang pharmaceutical co., LTD., co., LTD. And Shanghai in the first half of this year, Chinese medicine yinpian business to achieve high growth.
In the first half of 2017, the sales volume of traditional Chinese medicine products reached about 185 million yuan, with a growth rate of 493.2 percent. The rapid growth of sales revenue mainly benefited from the beginning of the consolidated statement of tongji traditional Chinese medicine and Shanghai tongji tang. In addition, we continue to benefit from the support and favorable market environment of the traditional Chinese medicine industry and the rapid growth of the pan-fry business.
Red sun pharmacy: strategic adjustment, increase sales channel control
Figure 3. Business income of each business sector of the red sun pharmaceutical industry in the first half of the 17th half year (unit: billion yuan)
In the first half of 2017, the company realized revenue of 14.43 billion yuan, down 17.36% year on year. Among them, the business revenue of traditional Chinese medicine recipe particle business reached 817 million yuan, down 6.47% year on year. Center daily news, according to the company is mainly engaged in the index was the main reason for the reduced over the same period last year is affected by multiple industry policy, in guarantee under the premise of not affected by the large terminal market, the company increased the sales channel control dynamics, the tightening of credit policy. The strategic adjustment above is laying the groundwork for efficient market development in the future, said the company.
Subsidiary Beijing Kang Rentang main products for traditional Chinese medicine formula particles, in the first half of 2017 Beijing Kang Rentang preparation workshop continue ameba management way, at the same time to upgrade the production equipment, further improve the production efficiency. The company is actively participating in the preparation and formulation of the national quality standard of formula granules.
In addition, under the background of the integration of the beijing-tianjin-hebei region coordinated development, youthful hebei red sun medicine pharmaceutical and safe medicine group joint investment projects, construction of traditional Chinese medicine formula granules production relying on Beijing Kang Rentang production system and quality standards, to grasp the opportunity, to let go of the traditional Chinese medicine formula particles policies rapidly promote the development of traditional Chinese medicine formula particles industry in hebei province, occupied more TCM formula granules market share as soon as possible.
Formula particles business facing policy liberalisation of the new environment, opportunity and challenge coexist red sun pharmaceutical industry has been in process quality standards, product quality, the brand has accumulated certain advantages, the future of traditional Chinese medicine (TCM) by clinic, wearable devices, such as remote device has reserve business ability, for the various levels of doctors provide enhanced, inheriting the experience of medical services, to increase the market development ability, realize the business promotion. In the second half of the year, the company will continue to optimize the production and supply chain and other backstage capabilities, upgrade the acquisition capacity of medicinal materials resources, and complete the construction of "automatic production base project of traditional Chinese medicine products" as planned.
Xiangxue pharmaceutical: the business growth of Chinese medicine is 75.70%
Figure 4. Business income of xiangxue pharmaceutical business sector in the first half of 17th year (unit: billion yuan)
In the first half of 2017, xiangxue pharmaceutical realized its operating revenue of 11.17 billion yuan, a year-on-year increase of 37.23%. Among them, the business revenue of traditional Chinese medicine and beverage business exceeded 400 million yuan, an increase of 75.70 percent from the same period a year ago. Xiangxue pharmacy said, thanks to completed the acquisition of hubei days in April 2016, at the same time to broaden the sales of Chinese medicine yinpian, on the basis of the company to strengthen hospital channel, extending chain and the third terminal.
According to the report, xiangxue made the smart frying center as the grip, expanding the market and enhancing customer adhesion. Formed a Chinese herbal medicine resources engineering technology center, according to group all category management of product planning, in the nine categories of products under the framework of product development, the main products are being developed is refined yinpian series, the series of medicinal food health, ordinary series slices. Company actively do a good job in building yinpian management platform, integration of market resources, based on the existing Chinese medicine planting base, the expansion of Chinese medicinal materials supply base, stable starting varieties of Chinese herbal medicine big run, take market share. At present, sichuan nanchong base has been put into operation, the initial formation is given priority to with toxic yinpian yinpian supply center of sichuan region, guangzhou yinpian plant put into operation, as a platform for integration of small and medium-sized slices in guangzhou factory, collaborative Shanghai qiaocheng pharmaceuticals, hubei day, sichuan nanchong base, constantly promote Chinese medicine yinpian supply company.
In addition, in the first half of this year, a subsidiary of hubei day bashing our pharmaceutical economy, Shanghai is respectively set up wholly owned subsidiary of hubei day economic wisdom technology co., LTD and jinan xiangxue wisdom of traditional Chinese medicine of traditional Chinese medicine science and technology co., LTD., aims to further develop wisdom of traditional Chinese medicine health care business, improve the market share of Chinese medicine yinpian business.
On August 26, xiangxue pharmacy, according to the announcement has agreed to receive food drug administration of guangdong province to carry out the traditional Chinese medicine formula particles pilot research production in the province's approval, the company said, as a result, on the one hand to the rich product structure, improve the traditional Chinese medicine resources of the whole industry chain layout, meet the market demand, further expand the brand effect and market share; On the other hand, it is beneficial to the layout of the whole industrial chain of traditional Chinese medicine, to strengthen the company's superiority in the traditional Chinese medicine industry and enhance its core competitiveness.
Tailong pharmaceutical: the business growth of traditional Chinese medicine is 9.93%
Figure 5. Business income of all business sectors of tai lung pharmaceutical in the first half of the year (unit: billion yuan)
In the first half of 2017, tailong pharmaceutical realized operating revenue of 493 million yuan, an increase of 20.89 percent from the same period last year. The business revenue of the traditional Chinese medicine beverage business reached 237 million yuan, up 9.93 percent from the same period last year.
Too Chinese medicine yinpian business focused on the subsidiary of dragon pharmaceutical tong jun don, tong jun hall during the first half of this year we will continue to increase the depth of the market development, on the basis of consolidating the original client business constantly develop new markets, relying on the tong jun hall to drive sales growth in the region of 6.9125 million yuan. We will continue to promote the growth of the sales of beverage tablets through measures such as improving the service of drug decoction. In order to further develop the henan market, during the reporting period tong jun hall set up henan tong jun tong pharmaceutical co., LTD., a registered capital of 3 million yuan, the influence of the promoted brand in henan tong jun hall, promote yinpian has been a steady rise in sales, the region during the reporting period yinpian sales increase of 3.6837 million yuan. The company's raw material purchase extends to the place of origin, improving the quality of raw materials and controlling the purchasing cost.
Hall of tong jun, clinic of traditional Chinese medicine, Chinese medicine yinpian mainly supplied to Chinese general hospital and pharmaceutical retail use, and by providing generation decoct Chinese traditional medicine and other value-added services, improve competitiveness, promote the sale of slices.
Conclusion Chinese medicine yinpian is one of the three pillars of traditional Chinese medicine (TCM) industry in China, in recent years, with the progress of science and technology, the traditional Chinese medicine yinpian as raw material, through the extraction, separation, concentration, drying, granulating, packaging, such as production technology, processing into a unified specification, unified dose, unified quality standards of new prescription drugs, traditional Chinese medicine formula particles entered the market, has become another piece of treasure of traditional Chinese medicine (TCM) industry in China.
The ministry recently released by the pharmaceutical industry in the first half of 2017, according to the main economic indicators to complete the first half of this year, pharmaceutical and industrial enterprises above designated size implementation main business income is 1.53144 trillion yuan, up 12.39% from a year earlier, the growth rate increased by 2.25% year-on-year. Among the sub-sectors, the most rapid growth was in the processing of traditional Chinese medicine, which reached 1047.88 billion yuan in the first half of the year, up 21.33% from the same period last year, up 8.3 percentage points from a year earlier.
Several leading enterprises, the sig pharmaceutical and xiangxue pharmacy originally in the field of Chinese medicine yinpian has good performance and market position, for traditional Chinese medicine formula particles in succession in guangdong this year pilot approval, then see how they develop TCM formula granule business, how to create new glory for performance.
|
